Vor to Participate in Two Upcoming Investor Conferences
08 nov. 2021 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief...
Vor to Present New Platform and Preclinical Data at ASH
04 nov. 2021 09h15 HE
|
Vor Biopharma
Knock out of CD123 or CLL-1 by CRISPR-Cas9 from Human Hematopoietic Stem Cells Maintains Hematopoietic Function and is Resistant to Targeted TherapiesMultiplex Engineering of Human CD34+ HSPCs Enables...
Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT
19 oct. 2021 07h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of data from its novel...
Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management
12 oct. 2021 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as...
VOR33 Granted U.S. FDA Fast Track Designation for AML
09 sept. 2021 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration...
Vor to Participate in Three Upcoming Investor Conferences
02 sept. 2021 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today announced that the Company will be participating in...
Vor Reports Second Quarter 2021 Financial Results and Provides Company Update
09 août 2021 16h05 HE
|
Vor Biopharma
On track to report initial VOR33 clinical data in the first half of 2022Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignanciesInitiated...
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
08 juil. 2021 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with...
Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs
17 juin 2021 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company) announced today that it will build-out an in-house clinical manufacturing facility in Cambridge,...
Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp
11 juin 2021 08h00 HE
|
Vor Biopharma
Mr. Patterson brings nearly 30 years of senior leadership experience in biotechnology, including leading Audentes Therapeutics from inception through acquisition over an eight-year periodKush M....